AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism.

The Calypso trial (NCT05778071) of eneboparatide, an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint of a composite of normalisation of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy.